| Literature DB >> 16434384 |
Franck Emmanuel Nicolini, Kaddour Chabane, Jean-Michel Cayuela, Philippe Rousselot, Xavier Thomas, Sandrine Hayette.
Abstract
Imatinib mesylate has become the gold standard front-line treatment of chronic myelogenous leukemia through its ability to inhibit ABL tyrosine kinase. Resistance to this inhibition may occur. We investigated the role of the K247R polymorphism in persistent sensitivity.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16434384
Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941